Chimiothérapie en phase précoce d'hormonorésistance des cancers de prostate métastatiques : quelles indications ?

25 juin 2010

Auteurs : S.J. Drouin, M. Rouprêt, H. Wallerand, N. Houédé
Référence : Prog Urol, 2010, 20, S192, suppl. S3




 



Le texte complet de cet article est disponible en PDF.
Cliquer ici pour le visualiser



Références



Grossmann M.E., Huang H., Tindall D.J. Androgen receptor signaling in androgen-refractory prostate cancer J Natl Cancer Inst 2001 ;  93 : 1687-1697 [cross-ref]
Tannock I.F., Osoba D., Stockler M.R., Ernst D.S., Neville A.J., Moore M.J., et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points J Clin Oncol 1996 ;  14 : 1756-1764 [cross-ref]
Yagoda A. Cytotoxic agents in prostate cancer: an enigma Semin Urol 1983 ;  1 : 311-321
Tannock I.F., de Wit R., Berry W.R., Horti J., Pluzanska A., Chi K.N., et al. Docétaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 2004 ;  351 : 1502-1512 [cross-ref]
Petrylak D.P., Tangen C.M., Hussain M.H., Lara P.N., Jones J.A., Taplin M.E., et al. Docétaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 2004 ;  351 : 1513-1520 [cross-ref]
Berthold D.R., Pond G.R., Soban F., de Wit R., Eisenberger M., Tannock I.F. Docétaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study J Clin Oncol 2008 ;  26 : 242-245 [cross-ref]
Beer T.M., Ryan C.W., Venner P.M., Petrylak D.P., Chatta G.S., Ruether J.D., et al. Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docétaxel with placebo plus docétaxel Cancer 2008 ;  112 : 326-330 [cross-ref]
Eymard J.C., Oudard S., Gravis G., Ferrero J., Theodore C., Priou F., et al. Second line chemotherapy with docétaxel (D) in men treated with docétaxel-based regimen for metastatic hormone-refractory prostate cancer (mHRPC) ASCO Prostate Cancer Symposium 2007 ;
Ohlmann C.H., Engelmann U., Heidenreich A. Second line chemotherapy with docétaxel for prostate-specific antigen (PSA) relapse in men with hormone-refractory prostate cancer previously treated with docétaxel-based chemotherapy ASCO Prostate Cancer Symposium 2006 ;
Timsit M.O., Lebret T., Mejean A. [Chemotherapy of hormono-refractory and hormonoresistant metastatic prostate cancer] Prog Urol 2008 ;  18 (Suppl 7) : S365-S375
Attard G., Reid A.H., A’Hern R., Parker C., Oommen N.B., Folkerd E., et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer J Clin Oncol 2009 ;  27 : 3742-3748 [cross-ref]
Scher H.I., Beer T.M., Higano C.S., Taplin M.E., Efstathiou E., Anand A., et al. Antitumor acitivity of MDV3100 in a phase I/II study of castration-resistant prostate cancer IJ Clin Oncol 2009 ;  27 (Suppl) : Abs n° 5011.
Berthold D.R., Pond G., DeWit R., Eisenberger M., Tannock I.F. Docétaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival of the TAX 327 study J Clin Oncol 2007 ;  25 (Suppl) : Abs n° 5005.
Armstrong A.J., Halabi S., Tannock I.F., George D.J., de Wit R., Eisenberger M. Development of risk group in metastatic castration-resistant prostate cancer (mCRPC) to facilitate the identification of active chemotherapy regimens J Clin Oncol 2009 ;  27 (Suppl) : Abs n° 5137.
Armstrong A.J., Garett-Mayer E., de Wit R., Tannock I.F., Eisenberger M. Prediction of survival following first line chemotherapy in men with castration-resistant metastatic prostate cancer Clin Cancer Res 2009 ; [Epub ahead of print].






© 2010 
Elsevier Masson SAS. Tous droits réservés.